Flamel Technologies S.A.(Flamel) is a biopharmaceutical company principally engaged in the development of two polymer-based drug delivery technologies for the improvement of medical applications. The Company’s Medusa nanoparticulate technology is designed to deliver therapeutic proteins, peptides and other large and small molecules injected subcutaneously. The Micropump technology is a multiparticulate technology for oral administration of small molecule drugs with applications in controlled-release, taste-masking and bioavailability improvement. The Trigger-Lock technology is an adaptation of Micropump designed to prevent the misuse of medications subject to abuse and to avoid dose dumping in the presence of alcohol. The Company is engaged in development and commercialization of controlled-release therapeutic products based on its polymer based technology.